Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Construction in progress, gross by Quarter
Construction in progress (MITC facilities & Norwood expansion), gross ($M) ($M)
Moderna Construction in progress, gross: $279M in Q2 2026, down 69.4% from a year earlier.
Latest, Q2 2026
279
Period ended Jun 30, 2026
Change on a year earlier
-69.4%
913 in Q2 2025
History
30 quarters
Since Q4 2018
Sources
29
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 8 (Balance Sheet Details).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Construction in progress (MITC facilities & Norwood expansion), gross ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 279 | -69.4% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 268 | -75.1% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 298 | -71.8% | Form 10-Q (filed 2026-07-31) ↗ |
| Q3 2025 | Sep 30, 2025 | 350 | -64.1% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 913 | -5.0% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,078 | +24.6% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,057 | +22.9% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 975 | +35.4% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 961 | +65.7% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 865 | +133.8% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 860 | +206.0% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 720 | +113.0% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 580 | +104.2% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 370 | +49.8% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 281 | +32.5% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 338 | +113.9% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 284 | +242.2% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 247 | +292.1% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 212 | +505.7% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2021 | Sep 30, 2021 | 158 | +406.4% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 83 | +543.4% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 63 | – | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 35 | +993.8% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 31.2 | +420.0% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 12.9 | +19.4% | Form 10-Q (filed 2020-08-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 3.20 | -31.9% | Form 10-K (filed 2021-02-26) ↗ |
| Q3 2019 | Sep 30, 2019 | 6 | – | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 10.8 | – | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 11.4 | – | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 4.70 | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Moderna Construction in progress, gross ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ppe-gross-cip
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.